Class information for:
Level 1: ERECTILE DYSFUNCTION//INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH//VARDENAFIL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
932 2869 33.7 77%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
622 13185 ERECTILE DYSFUNCTION//JOURNAL OF SEXUAL MEDICINE//INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 ERECTILE DYSFUNCTION Author keyword 537 32% 48% 1370
2 INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH Journal 97 25% 12% 340
3 VARDENAFIL Author keyword 87 46% 5% 141
4 SILDENAFIL Author keyword 76 21% 11% 324
5 TADALAFIL Author keyword 69 34% 6% 166
6 JOURNAL OF SEXUAL MEDICINE Journal 61 14% 15% 417
7 IMPOTENCE Author keyword 37 16% 7% 210
8 CARDIOVASC DIS SEXUAL HLTH UNIT Address 29 88% 0% 14
9 ERECTION HARDNESS Author keyword 26 100% 0% 11
10 PHOSPHODIESTERASE TYPE 5 INHIBITORS Author keyword 25 38% 2% 52

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 ERECTILE DYSFUNCTION 537 32% 48% 1370 Search ERECTILE+DYSFUNCTION Search ERECTILE+DYSFUNCTION
2 VARDENAFIL 87 46% 5% 141 Search VARDENAFIL Search VARDENAFIL
3 SILDENAFIL 76 21% 11% 324 Search SILDENAFIL Search SILDENAFIL
4 TADALAFIL 69 34% 6% 166 Search TADALAFIL Search TADALAFIL
5 IMPOTENCE 37 16% 7% 210 Search IMPOTENCE Search IMPOTENCE
6 ERECTION HARDNESS 26 100% 0% 11 Search ERECTION+HARDNESS Search ERECTION+HARDNESS
7 PHOSPHODIESTERASE TYPE 5 INHIBITORS 25 38% 2% 52 Search PHOSPHODIESTERASE+TYPE+5+INHIBITORS Search PHOSPHODIESTERASE+TYPE+5+INHIBITORS
8 PDE5 INHIBITORS 23 39% 2% 46 Search PDE5+INHIBITORS Search PDE5+INHIBITORS
9 PDE5 INHIBITOR 15 36% 1% 35 Search PDE5+INHIBITOR Search PDE5+INHIBITOR
10 AVANAFIL 15 67% 0% 14 Search AVANAFIL Search AVANAFIL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INTERNATIONAL INDEX 203 43% 13% 366
2 IMPOTENCE 203 29% 21% 599
3 SILDENAFIL CITRATE 136 38% 10% 289
4 SILDENAFIL CITRATE VIAGRAR 87 86% 2% 44
5 ERECTILE DYSFUNCTION 80 13% 21% 589
6 INCREASES PENILE RIGIDITY 77 89% 1% 34
7 FUNCTION IIEF 71 63% 3% 72
8 ORAL SILDENAFIL 69 30% 7% 190
9 SEXUAL DYSFUNCTION 68 20% 11% 311
10 TADALAFIL 49 34% 4% 120

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH 97 25% 12% 340
2 JOURNAL OF SEXUAL MEDICINE 61 14% 15% 417
3 REVISTA INTERNACIONAL DE ANDROLOGIA 2 11% 1% 16

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease 2014 22 66 82%
Lifestyle modifications and erectile dysfunction: what can be expected? 2015 2 69 77%
Sexual Dysfunction Related to Drugs: A Critical Review. Part IV: Cardiovascular Drugs 2015 2 79 59%
THERAPY OF ENDOCRINE DISEASE Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis 2015 2 59 59%
A Systematic Review of the Psychosocial Outcomes Associated with Erectile Dysfunction: Does the Impact of Erectile Dysfunction Extend Beyond a Man's Inability to Have Sex? 2014 6 68 85%
Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis 2013 22 37 78%
Clinical significance of erectile dysfunction developing after acute coronary event: exception to the rule or confirmation of the artery size hypothesis? 2015 1 26 85%
Sexual counseling and cardiovascular disease: practical approaches 2015 1 37 84%
Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator 2003 214 19 89%
Erectile Dysfunction in Diabetes Mellitus 2009 87 120 53%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CARDIOVASC DIS SEXUAL HLTH UNIT 29 88% 0.5% 14
2 SEXUAL REPROD HLTH 15 35% 1.2% 35
3 UROL SEXUAL DIS 11 100% 0.2% 6
4 SEXUAL FUNCT ENDOCRINOL 8 50% 0.4% 12
5 SEXUAL REHABIL CLIN 8 75% 0.2% 6
6 SPECIALTY OBSTET GYNECOL 6 100% 0.1% 4
7 CHICAGO CORE BIOMEASU POPULAT BASED AGING 4 75% 0.1% 3
8 UNITA UROL ANDROL 4 75% 0.1% 3
9 CESEX 4 56% 0.2% 5
10 PYRAH UROL 3 21% 0.5% 15

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000227095 CORPUS CAVERNOSUM//ERECTILE DYSFUNCTION//HUMAN CORPUS CAVERNOSUM
2 0.0000176002 IMPOTENCE//PENILE REVASCULARIZATION//VENOUS LEAKAGE
3 0.0000168314 ENT HEAD NECK CANC//AIDS PREVENT CONTROL COMM//DERMATOL VENERIOL
4 0.0000160028 PDE 5 INHIBITION//PDE5//PHOSPHODIESTERASE 5
5 0.0000123194 FUNCTIONAL STATEMENT//EXAMINATION DIAGNOSTIC TESTING//FEMALE PAIN PATIENTS
6 0.0000105098 FEMALE SEXUAL DYSFUNCTION//HYPOACTIVE SEXUAL DESIRE DISORDER//JOURNAL OF SEX & MARITAL THERAPY
7 0.0000092027 CHRONIC RENAL FAILURE AND SEXUAL DYSFUNCTION//NEPHROL DIALYSOTHER Y INTERNAL MED//SEXUAL HEALTH IN MEN
8 0.0000089801 PREMATURE EJACULATION//DAPOXETINE//INTRAVAGINAL EJACULATORY LATENCY TIME
9 0.0000089583 SILDENAFIL ANALOGUE//TADALAFIL ANALOGUE//HOMOSILDENAFIL
10 0.0000075912 PENILE REHABILITATION//CAVERNOUS NERVE//RADICAL PROSTATECTOMY